Mary Ogden
Family · Chattanooga, TNNPI 1043392715
Payments from drug & device makers
Across 79 payments — averaging $17.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$345
- Travere Therapeutics, Inc.$225
- Vifor Pharma, Inc.$113
- Bayer$104
- Mallinckrodt Hospital Products Inc.$103
- Aurinia Pharma U.S., Inc.$88
- plus $377 from 14 others
What the payments were for
- Food & beverage$1,350100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 20 | $345 |
| Travere Therapeutics, Inc. | 15 | $225 |
| Vifor Pharma, Inc. | 6 | $113 |
| Bayer | 6 | $104 |
| Mallinckrodt Hospital Products Inc. | 4 | $103 |
| Aurinia Pharma U.S., Inc. | 6 | $88 |
| Amgen(2 entities) | 5 | $78 |
| AstraZeneca | 3 | $47 |
| GSK | 2 | $31 |
| Kyowa Kirin, Inc. | 2 | $30 |
| Novartis | 1 | $27 |
| OPKO Pharmaceuticals, LLC | 1 | $22 |
| Calliditas Therapeutics US Inc. | 1 | $22 |
| Sanofi | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Apellis Pharmaceuticals, Inc. | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Shield Therapeutics Inc | 1 | $13 |
How this compares
$1,355 in reported general payments places this provider in the 70th percentile of 6,706 family providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 16 | $12,306 |
| Cinacalcet Hcl | 22 | $5,424 |
| Potassium Chloride | 104 | $2,995 |
| Torsemide | 54 | $848 |
| Calcitriol | 62 | $819 |
| Bumetanide | 21 | $744 |
| Valsartan | 14 | $727 |
| Losartan Potassium | 50 | $723 |
| Hydralazine Hcl | 59 | $650 |
| Doxazosin Mesylate | 21 | $622 |
| Amlodipine Besylate | 82 | $620 |
| Spironolactone | 45 | $553 |
| CefuroximeCefuroxime Axetil | 69 | $536 |
| Carvedilol | 47 | $479 |
| Furosemide | 88 | $400 |
Paid to pharmacies, not to this prescriber.
Other family in Chattanooga
- Jennifer SparksChattanooga$120K
- Marcie BeasleyChattanooga$91K
- Amy RainsChattanooga$55K
- Bronte NaplesChattanooga$26K
- Ernest BrandtChattanooga$21K
- Stacy BrownMt Juliet$719K
- Dana WebberKnoxville$499K
- Brandy BiedermanHixson$448K
- Cynthia MillerMurfreesboro$384K
- Tamera ThoenerNashville$254K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.